Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies

About five to 10 percent of leukemia patients are estimated to carry a germline variant predisposing them to MDS/AML [1]. In specific situations, leukemia risk is even higher and amounts up to 70% for MDS with monosomy 7 in adolescents [2]. In addition to specific somatic chromosome aberrations such as monosomy 7, features indicative of a genetic predisposition are multiple malignancies, family history of hematological neoplasms, long-lasting thrombocytopenia, not explained by other reasons, congenital abnormalities, excessive treatment toxicities, delay count recovery after chemotherapy or poor stem cell mobilization [3, 4].

In contrast to sporadic leukemia, where only the leukemic cells carry genetic variants, in familial leukemia all cells of the body carry a germline variant. These germline variants may occur de novo, but in many cases, they are inherited and may be passed from one generation to the next. Most leukemia risk syndromes are inherited in an autosomal dominant fashion, with a 50% (1:2) chance for children to inherit the causative germline variant. Not every individual carrying the germline variant will develop disease, some might have no symptoms or only show mild cytopenia—a phenomenon called reduced penetrance [5]. Examples for autosomal recessive inherited diseases with high MDS/AML risk are classical bone marrow failure syndromes such as Fanconi anemia (FA) and Shwachman-Diamond syndrome, examples for X-linked inheritance are some forms of dyskeratosis congenita (DKC1) or FA (FANCB) and the immunodeficiency Wiskott-Aldrich syndrome. For these disorders, detailed guidelines and expert recommendations exist [6‐9].

In 2016 WHO has recognized myeloid neoplasms with germline predisposition as a new entity (Table 1) [10, 11]. They are classified as (1) neoplasms with germline predisposition without pre-existing conditions (e.g. CEBPA, DDX41), (2) neoplasms with a history of thrombocytopenia (RUNX1, ANKRD26, ETV6) and (3) neoplasms with other organ dysfunction (e.g. GATA2 or telomere biology disorders).

In the meantime, a number of additional risk gene loci have been identified (Fig. 1) [12]. It has become clear, that the spectrum of hematologic malignancies in certain genetic tumor risk syndromes contains myeloid, but also lymphoid neoplasms [13, 14]. In Li-Fraumeni syndrome, typical leukemia subtypes are MDS/ AML with complex karyotypes, but also hypodiploid acute lymphoblastic leukemia (ALL) [15]. In RUNX1-familial platelet disorder with myeloid malignancies (FPDMM), MDS/ AML, but also T-ALL may occur [16]. Also ETV6-associated familial leukemias comprise both myeloid and lymphoid neoplasms [17]. For patients with pathogenic germline variants in PAX5 [18‐20] and IKZF1 [21], lymphoid leukemias have been reported. Infection stimuli may play a role in leukemogenesis in predisposed individuals [22].

A recent study performed in a cohort of 86 families with MDS/AML established germline variants with a high or moderate level of evidence for gene-disease association in 16 genes previously associated with malignancies in 57% (49 families) [23]. In a further uncharacterized 37 families 65 new candidate loci were identified. These included genes that are known to be mutated in inherited hematological disorders, including ADA, GP6, IL17RA, PRF1, SEC23B, DNAH9, NAPRT1, SH2B3 or novel loci, e.g. DHX34. Notably, the most frequently affected gene was RUNX1, which was mutated in 12% of the patients. In addition to single nucleotide variants (SNVs), truncating and splice site variants, a significant number of copy number variants such as complete RUNX1 deletions were detected. This has to be considered when selecting methods for the identification of genetic variants [24].

Since the diagnosis of familial leukemia has critical implications for the patient and for his/her family, it is important to recognize clinical features pointing towards genetic predisposition [1]. In 2016 Jongmans et al. have described easy to use recognition criteria of genetic predisposition in pediatric cancer patients [25]. They include (1) family history, (2) specific cancer entities, (3) somatic hints, (4) ≥ 2 malignancies, (5) congenital defects/ non-malignant signposts, (6) high/unexpected toxicity. These criteria have been updated by the German Societies of Paediatric Hematology and Oncology and Human Genetics in a questionnaire designed for use in every pediatric hematology oncology center [26]. It is requested to take a 3-generation pedigree to evaluate the family history, to document diagnosis of neoplasms or known germline predisposition determined by genetic tumor analysis, two or more known malignancies or the presence of a child with cancer and congenital or other anomalies, and, finally, whether the patient has suffered from excessive toxicity from cancer therapy. Furthermore, these criteria include specific cancer entities, among them ALL with Robertsonian translocation rob(15;21), hypodiploid ALL, AML with monosomy 7, and MDS in general. Other features are somatic hits suggesting a germline predisposition, more than two malignancies in the diseased child, a number of defined congenital defects or high/ unexpected toxicity [26].

The Nordic guidelines established by the Nordic MDS group initially focused on adults with germline predisposition to myeloid neoplasms and are intended for use in clinical practice [27]. They provide most detailed recommendations, based on the recent literature and clinical experience of the group, for the identification of individuals with genetic predisposition for hematological malignancies. These guidelines contain clear algorithms on who should be offered genetic testing based on age, family history, personal medical history, clinical/ physical findings and genetic characterization of the clonal cells, e.g. they identify patients below the age of 50 with monosomy 7, del(7q) or der(1;7) as possible candidates for familial leukemia, who should, therefore, be investigated for cancer predisposition genes. In clinical studies, it is recommended to investigate even all patients below 50 years of age (Table 1).

Since leukemia patients with genetic predisposition may need special clinical care, the 2017 ELN recommendations [11] have already stated the importance of identifying these patients. Affected patients, and their families, should be offered genetic counseling with a counselor familiar with these disorders. Recently, the Nordic MDS group has published the Nordic guidelines for germline predisposition to myeloid neoplasms in adults within an EHA guideline article. The Nordic guidelines contain very concise and clear recommendations for diagnostic work-up, genetic diagnosis, clinical management and follow-up. Most importantly, they see a close collaboration between hematologists and clinical geneticists as mandatory [27]. Genetic counseling should be offered to all patients investigated for potential germline conditions, even if no pathogenic variant is detected. Genetic counseling is highly recommended prior to genetic testing of all patients, (e.g. upon detection of a potential germline variant in clonal cells of an MDS/ AML patient), and also prior to genetic testing of apparently healthy relatives including predictive testing of HLA-identical potential family donors. The American Association for Cancer Research (AACR) also highly recommends referral to specialized centers with expertise in hereditary hematologic malignancies including hematologists-oncologists and geneticists to enable coordinated and comprehensive care [28]. Talking points to discuss with families include genetic risk, clinical management of hematologic and non-hematologic malignancies, screening, and participation in research programs. Moreover, the expert group found it important to educate the families about signs and symptoms of leukemia and to initiate an early consultation with transplant specialists. If genetic testing of siblings and parents is planned to exclude mutation carriers as stem cell donors, pre- and post-test genetic counselling should be provided [28].

There is a scientific debate as to what tissue serves best as a source of germline DNA for hematopoietic malignancies. The Nordic MDS group recommends the use of skin fibroblasts and isolated T cells.

Simon et al. have suggested investigating buccal swaps or saliva obtained at diagnosis [29]. Pairwise comparison of this “normal DNA” with AML samples followed two criteria: (1) the suggested germline variant (e.g. RUNX1) should show a variant allele frequency of nearly 50% in the normal DNA, (2) in contrast to the germline variant, additional genetic markers such as NRAS should only be present in the AML sample but not in normal DNA [30‐32]. Using this approach, 12 of 44 RUNX1 pathogenic variants have been validated to be of germline origin [29]. Even though this approach holds undeniable advantages over the usage of bone marrow aspirates, the possibility of multiple clonal somatic variants with different allele frequencies still have to be kept in mind. In case of remission bone marrow aspirates or peripheral blood remain an option, provided that the methods necessary to measure any residual blast contamination are available.

It is a challenge to discriminate mosaicism, i.e. the presence of genetic variants in different organs and tissues developing due to post-zygotic events, from clonal hematopoiesis, i.e. somatic variants in genes known to be drivers of hematologic malignancy leading to an expansion of hematopoietic cells. [33, 34] If this question arises, not only peripheral blood or bone marrow, but additional tissues have to be investigated [35].

The Spanish guidelines for the use of targeted deep sequencing in MDS and CMML include a section about genetic predisposition to be considered for variants with a variant allele frequency close to 50% or 100%. These variants should be evaluated within each patient’s clinical and familial context [36]. When a germline variant is confirmed, referral of patients to professionals with expertise in cancer predisposing syndromes and in genetic counselling is recommended. In line with these recommendations, the Nordic guidelines recommend further investigating somatic variants near heterozygosity (variant allele frequency (VAF) 40–60%), near homozygosity (VAF above 90%) and specific types of variants such as truncating DDX41 variants.

Genetic testing to unravel a pathogenic germline variant in a gene responsible for predisposition to hematological malignancies should follow established quality criteria [37]. Only validated and accredited methods should be used to detect SNVs and CNVs including noncoding regulatory regions (e.g. in the GATA2 intron 4). If panel analyses are used for the detection of SNV, array-based methods such as arrayCGH are mandatory for the identification of large deletions. As mentioned, large deletions comprise a significant portion of pathogenic variants, particularly in the RUNX1 gene [23, 38].

In recent years, synonymous mutations (nucleotide changes in exonic regions that do not alter amino acid sequence and are usually excluded from the analytic pipelines) have been gaining attention as potential pathogenic mutations. For example, in GATA2 deficiency they account for ~ 6% of all cases and were shown to cause RNA degradation as confirmed by RNA sequencing [39]. The authors proposed a cascade approach where RNA sequencing follows inconclusive DNA analysis in patients with high index of suspicion for a specific Mendelian disorder but without a known pathogenic mutation. Another study performed in a cohort of families undergoing evaluation for hereditary cancer found that RNA genetic testing improves the interpretation of genetic variants found by DNA sequencing [40]. Evidence from RNA testing clarified the interpretation of 88% (49/56) of inconclusive cases, reclassifying them either as clinically actionable or as benign.

The distinction between (likely) benign and (likely) pathogenic variants is often difficult. According to the internationally accepted ACMG recommendations Richards et al. [41] have described benign variants as class 1, likely benign variants as class 2, VUS as class 3, likely pathogenic variants as class 4 and pathogenic variants as class 5. Criteria to determine the pathogenicity of a variant include cosegregation within the family, affecting a highly conserved region, disrupting a functionally important protein domain, complete loss of the gene, generation of a new slice site inducing exon skipping and a population frequency < 0.0001. For in silico prediction of disease-causing effects evolutionary conservation, functionally important protein domains, potential splice effects, conformational changes, homo-/heterozygosity, cis/trans, and familial segregation are considered. However, definitive proof for pathogenicity often requires functional studies. In the meantime, specific recommendations for the interpretation of TP53 and RUNX1 variants have been published [42, 43].

Since many families with hereditary cancers have unique and often novel mutations, a substantial number of variants identified are VUS. If a genetic alteration has been classified as VUS, it cannot be included in a clinical report as having clinical significance. However, insights from experts (who might know of additional patients with identical mutations, not previously published or deposited in variant databases such as ClinVar) might help reclassifying such VUS changes. Therefore, interdisciplinary variant interpretation boards or consortia will be key to improved classification of germline variants. A VUS may be included in a clinical report for future reference in case that it is reclassified and becomes clinically relevant. Until a VUS is successfully classified, however, there should be no clinical significance resulting from it. It has to be noted that extensive research and publication of data are needed before a VUS may become clinically relevant.

The screening program is recommended only for patients with (likely) pathogenic variants, but not for variants of unknown significance and should also be offered to family members at risk [27].

According to the recent recommendations of the AACR [28], there is no benefit of screening in rapidly evolving leukemia such as AML or ALL. However, screening may be helpful for timing of allo-stem cell transplantation in some bone marrow failure syndromes predisposing for AML or MDS.

AACR recommends an annual surveillance testing with complete blood count (CBC) and bone marrow (BM) aspirate/biopsies with cytogenetics. At baseline CBC with differential, BM aspirate/biopsy with cytogenetics and a myeloid panel is recommended to investigate somatic variants. A CBC as a follow-up should be performed every six months for patients and family members at risk that carry RUNX1, GATA2 or Fanconi anemia pathogenic variants. Only in case of worsening CBC, BM aspirate/biopsy with cytogenetics and a myeloid genetic panel should be performed. An innovative recommendation is to do an annual blood testing for somatic pathogenic variants to follow clonal evolution [27]. Clonal hematopoiesis may be used to determine the time point for early intervention. These data should be evaluated in the context of the type and number of variants, the gene involved, the variant allele frequency (VAF), and also the dynamics over time.

It is also important to consider other organ manifestations such as the high risk for early breast cancer in females with Li-Fraumeni syndrome. Thus, children with hypodiploid ALL carrying pathogenic variants of TP53, should be included in intensive screening programs that have demonstrated improved outcome [44‐47]. Whenever possible, avoiding exogenic noxes such as repeated radiography and radiotherapy may help to decrease the risk of secondary cancer in Li-Fraumeni syndrome and other DNA repair deficiency syndromes.

Inherited genetic variants may tailor treatment and screening aiming at early intervention. The knowledge of inherited genetic variants may also be important for transplant planning (e.g. to exclude family members that also carry the genetic variant as possible donors).

In essence, expert centers with close collaboration of hemato-oncologist and clinical geneticists are needed to guide diagnosis, treatment and screening. Expert genetic counselling is essential to inform family members at risk and guide screening.

Statements regarding patients and healthy family members carrying pathogenic germline variants predisposing them to hematologic malignancies